OTCMKTS:MYCOF Mydecine Innovations Group - MYCOF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mydecine Innovations Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.38 -0.03 (-7.32%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.36▼$0.4450-Day Range$0.36▼$0.4752-Week Range$0.05▼$5.00Volume62,681 shsAverage Volume9,665 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlinesShort Interest About Mydecine Innovations Group (OTCMKTS:MYCOF) StockMydecine Innovations Group, Inc. operates as a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions. It encompasses three companies: Mindleap Health, Mydecine Health Sciences, and NeuroPharm Inc. The Mindleap Health is an advanced digital health platform that helps people connect with mental health specialists who can empower them to thrive and develop habits for a healthy mind. The Mydecine Health Sciences is a vertically integrated company developing novel fungtional mushroom products and psychedelic medicines for healthy and vulnerable populations. The NeuroPharm is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations. The company was founded by Parente Carman on September 27, 2013 and is headquartered in Vancouver, Canada.Read More Receive MYCOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MYCOF Stock News HeadlinesMarch 6, 2023 | finance.yahoo.comMydecine Announces Debt SettlementsJanuary 27, 2023 | seekingalpha.comKAVL Kaival Brands Innovations Group, Inc.March 26, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!December 13, 2022 | benzinga.comPsychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary BusinessNovember 15, 2022 | msn.comMydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 MonthsNovember 15, 2022 | finanznachrichten.deMydecine Innovations Group Inc.: Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022November 15, 2022 | finance.yahoo.comMydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022November 15, 2022 | finance.yahoo.comMydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022March 26, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!September 23, 2022 | finance.yahoo.comMYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFOSeptember 1, 2022 | finance.yahoo.comMydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.August 19, 2022 | finance.yahoo.comMydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of DirectorsAugust 17, 2022 | seekingalpha.comMydecine Innovations Group GAAP EPS of -C$0.35August 16, 2022 | finance.yahoo.comMydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022August 12, 2022 | finance.yahoo.comMYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORSJune 17, 2022 | finance.yahoo.comU.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking CessationJune 9, 2022 | finance.yahoo.comMydecine Provides Company Update; Welcomes New Board MemberMay 27, 2022 | proactiveinvestors.comMydecine Innovations closes 'best efforts' overnight marketed offering for aggregate gross proceeds of $2,814,199.50May 27, 2022 | finance.yahoo.comMydecine Announces Closing of Overnight Marketed Public Offering of UnitsMay 20, 2022 | proactiveinvestors.comMydecine announces overnight marketed public offering of unitsMay 19, 2022 | proactiveinvestors.comMydecine Innovations Group set to raise up to $4M in previously announced overnight public offeringMay 17, 2022 | seekingalpha.comMydecine Innovations Group GAAP EPS of -$1.20 misses by $0.41April 29, 2022 | benzinga.comMYDECINE INNOVATIONS GROUP FILES PROSPECTUS...April 27, 2022 | finance.yahoo.comMYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENTApril 14, 2022 | msn.comMydecine Announces 1-for-50 Reverse Stock SplitApril 13, 2022 | seekingalpha.comMydecine Innovations Group announces 1-for-50 reverse stock splitApril 1, 2022 | proactiveinvestors.com.auMydecine ends FY2021 with C$1.5M in cash to help propel mental health treatment initiatives in 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MYCOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MYCOF Company Calendar Last Earnings11/16/2021Today3/25/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MYCOF CUSIPN/A CIKN/A Webwww.mydecine.com Phone(813) 871-3936FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesDavid Joshua BartchChairman, President & Chief Executive OfficerDamon MichaelsChief Operating OfficerJohn Charles RossChief Financial OfficerRobert RoscowDirector & Chief Science OfficerRakesh JetlyChief Medical OfficerKey Competitors1933 IndustriesOTCMKTS:TGIFF4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFAcreageOTCMKTS:ACRHFView All Competitors MYCOF Stock - Frequently Asked Questions How have MYCOF shares performed in 2023? Mydecine Innovations Group's stock was trading at $0.43 at the beginning of 2023. Since then, MYCOF shares have decreased by 11.6% and is now trading at $0.38. View the best growth stocks for 2023 here. Are investors shorting Mydecine Innovations Group? Mydecine Innovations Group saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 300 shares, a decline of 50.0% from the February 13th total of 600 shares. Based on an average trading volume of 25,000 shares, the days-to-cover ratio is presently 0.0 days. View Mydecine Innovations Group's Short Interest. How were Mydecine Innovations Group's earnings last quarter? Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) issued its quarterly earnings results on Tuesday, November, 16th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.50. When did Mydecine Innovations Group's stock split? Mydecine Innovations Group shares reverse split before market open on Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is Mydecine Innovations Group's stock symbol? Mydecine Innovations Group trades on the OTCMKTS under the ticker symbol "MYCOF." How do I buy shares of Mydecine Innovations Group? Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mydecine Innovations Group's stock price today? One share of MYCOF stock can currently be purchased for approximately $0.38. How can I contact Mydecine Innovations Group? Mydecine Innovations Group's mailing address is 789 West Pender Street, Vancouver, BC V6C. The official website for the company is www.mydecine.com. The company can be reached via phone at (813) 871-3936. This page (OTCMKTS:MYCOF) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.